



# Reducing drug shortages and high prices

CIVICA  
MEDICATIONS  
ARE BEING  
USED TO TREAT

**30**  
MILLION  
PATIENTS

**66**

MEDICATIONS

**55**

HOSPITAL SYSTEM  
MEMBERS



**1,550**

HOSPITALS

**1/3**

OF U.S. LICENSED  
HOSPITAL BEDS

**Over the past two decades, shortages of generic, injectable drugs critical to the lifesaving work of hospitals in the U.S. have become commonplace.**

**These shortages are so ubiquitous that hospitals and health care systems now maintain permanent drug shortage response teams that seek alternatives to unavailable drugs. As a result, time that hospital pharmacists, technicians, nurses and others would prefer to spend caring for patients is spent ensuring that the patients who most need short-supply drugs get whatever supply is available. COVID-19 has only exacerbated this problem.**

Civica, a nonprofit generic drug company, was created to reduce and prevent drug shortages and the price spikes that can accompany them. Its mission, as driven by its governing board of hospital systems and philanthropies, is to make quality generic medicines accessible and affordable to everyone. Today, more than 55 health systems have joined Civica. They represent 1,550 hospitals and approximately one-third of all U.S. hospital beds. Civica has also begun to supply the U.S. Department of Veteran’s Affairs, the U.S. Department of Defense and the U.S. Strategic National Stockpile.

Civica was primarily created to improve the resiliency of the supply of essential medicines used in hospitals daily, often for critical care. The drugs we make are not those with the highest return on investment. Rather, they are the ones that are identified and prioritized by our health systems – by doctors and pharmacists on the front lines – as the medications most important for quality patient care. Eleven Civica medications are being used to help COVID-19 patients – these include neuromuscular blocking agents, sedation agents and pain management medications for patients on ventilators.

**Ensuring a safe and stable supply of essential medicines for U.S. patients.**

Civica medications have helped treat over 30 million patients to date. Civica brings together hospital systems and drug manufacturers to work collaboratively, ensuring drugs for hospitals and fair profits at predictable volumes for manufacturers. We’re building a 140,000 square-foot sterile injectable manufacturing facility in Petersburg, Virginia. The Civica manufacturing plant will employ nearly 200 people and will include disposable technology and advanced technology filling lines to produce **90 million vials** and **50 million pre-filled syringes** a year, steam sterilization capability, automated visual inspection and packaging lines, and controlled temperature warehousing of raw materials and finished medications. The facility will be built to accommodate future growth.

Construction of the Civica facility is well underway. We expect it to be operational in 2024 after building completion, a highly regulated sequence of equipment and product testing, FDA reviews, etc.

The first Civica medication to come out of the facility will be Civica’s affordable insulin. Once approved by the FDA, Civica insulin will be available beginning in 2024 to people with diabetes at significantly lower prices than insulins currently on the market. Learn more at [Civicarx.org](http://Civicarx.org)